〈Case Reports〉Recognition of complete response by long-term observation after treatment with ^<90>Y-Ibritumomab tiuxetan for relapsed follicular lymphoma

この論文にアクセスする

抄録

[Abstract] Monoclonal antibodies have markedly changed the treatment possibilities for patients with indolent B-cell lymphoma. ^<90>Y-Ibritumomab tiuxetan (Zevalin) is the first radioimmunotherapy (RIT) agent approved for the treatment of relapsed and refractory indolent lymphoma patients. In most cases, the maximum clinical response were observed two to three months after RIT. Treatment with ^<90>Y-ibritumomab tiuxetan may have potential late effects in some cases of relapsed follicular lymphomas, and we must be careful to start the next treatment after RIT.

収録刊行物

  • Acta Medica Kinki University

    Acta Medica Kinki University 36(2), 87-89, 2011-12-01

    The Kinki University Medical Association

各種コード

  • NII論文ID(NAID)
    120005736804
  • 本文言語コード
    ENG
  • 資料種別
    Departmental Bulletin Paper
  • ISSN
    03866092
  • データ提供元
    IR 
ページトップへ